retatrutide type 2 diabetes phase 2 results 2024 ada Positive Top-line for in Diabetes: TRANSCEND-T2D-1 ADA 2026: Retatrutide Revolution
Description
Of greater concern are potential risks from combination use: Hypoglycaemia risk: Retatrutide enhances insulin secretion in a glucose-dependent manner, which carries a low intrinsic hypoglycaemia risk when used alone
Hypothalamic obesity and GLP-1 and intervention and human revealed 54 results, and Hypothalamic obesity and GLP-1 and craniopharyngioma yielded an additional 6 results
Practical Considerations for Daily Life Beyond clinical efficacy data, practical considerations significantly impact treatment success
7.7 Ongoing Clinical Trials Further clinical trials of GLP-1 receptor agonists are currently ongoing
Your subscription renews automatically
doi: 10.1016/j.ejphar.2009.12.023 [DOI] [PubMed] [Google Scholar] 175
